Same Drug Class

Osimertinib vs Trastuzumab

Osimertinib vs Trastuzumab: Overview

This comparison examines the pharmacological differences between Osimertinib and Trastuzumab.

Mechanism of Action

Osimertinib: Third-generation irreversible EGFR TKI targeting T790M resistance mutation and activating mutations.

Trastuzumab: Anti-HER2 monoclonal antibody inhibiting receptor signaling.

Pharmacokinetics

Half-life: Osimertinib — 48 hours; Trastuzumab — 28 days.

Chemical Properties

Molecular Formula: Osimertinib — C28H33N7O2.

Molecular Weight: Osimertinib — 499.6050 g/mol.

Type: Osimertinib — Small molecule; Trastuzumab — Antibody.